

Curis Inc. (CRIS)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001108205

[illegible]

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

[illegible]

Business, in the company's words

opening of Item 1 of the 10-K received Mar 24, 2026

We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our

recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 98.6						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		64.1%	(6.6%)	98.6	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 97.6						
Twelve-month failure probability		24.01%	0.07%	100.0	248	2026-06-30
Altman Z double-prime		(207.55)	(0.31)	98.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		0.49x	2.96x	94.9	839	2025-12-31
Growth and financing, sleeve percentile 89.3						
Revenue growth, three-year compound		(2.4%)	10.0%	77.1	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(43.2%)	2.1%	97.6	704	2025-12-31
Net share issuance, one year		371.1%	2.5%	93.2	634	2026-03-20


Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 371.1%
Short runway	cash runway is 2.0 months
Distress	CHS probability 24.008539%; universe top-decile threshold 1.068854%

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
366	Alector, Inc. (ALEC)	98.6	E	short runway, fortress balance sheet
367	Atara Biotherapeutics, Inc. (ATRA)	98.9	E	dilution, short runway
368	HCW Biologics Inc. (HCWB)	99.2	E	dilution, short runway, late filer, degenerate inputs, fortress balance sheet
369	Inovio Pharmaceuticals, Inc. (INO)	99.5	E	dilution, short runway, degenerate inputs
370	PAVmed Inc. (PAVM)	99.7	E	dilution, short runway, degenerate inputs
371	Curis Inc. (CRIS) <	100.0	E	dilution, short runway, distress

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(95.5%)	8.0%	1
Distance from 52-week high	(97.8%)	(31.4%)	1
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(2,592.2%)	(1.0%)	0
Book value to price	3.17	0.28	99
Sales to price	6.37	0.31	98
Composite equity issuance, five years	221.2%	20.3%	92
Relative strength against the sector, log excess return	(3.32)	(0.14)	1

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail

Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$5.1M
Operating cash flow, four quarters	-\$30.6M
Months of runway	2.0
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$222,154

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$7.6M	2025-12-31	2026-03-24	10-K	0001108205-26-000043
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$27.2M	2025-12-31	2026-03-24	10-K	0001108205-26-000043
3	assets	us-gaap:Assets	\$20.0M	2025-12-31	2026-03-24	10-K	0001108205-26-000043
4	assets	us-gaap:Assets	\$41.3M	2024-12-31	2026-03-24	10-K	0001108205-26-000043
5	current assets	us-gaap:AssetsCurrent	\$6.9M	2025-12-31	2026-03-24	10-K	0001108205-26-000043
6	current liabilities	us-gaap:LiabilitiesCurrent	\$14.1M	2025-12-31	2026-03-24	10-K	0001108205-26-000043
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.2B	2025-12-31	2026-03-24	10-K	0001108205-26-000043
8	operating income	us-gaap:OperatingIncomeLoss	-\$5.7M	2025-12-31	2026-03-24	10-K	0001108205-26-000043
9	book equity	us-gaap:StockholdersEquity	\$5.5M	2025-12-31	2026-03-24	10-K	0001108205-26-000043
10	liabilities	us-gaap:Liabilities	\$14.5M	2025-12-31	2026-03-24	10-K	0001108205-26-000043
11	operating income	us-gaap:OperatingIncomeLoss	-\$42.1M	2021-12-31	2023-03-13	10-K	0001108205-23-000023
12	interest expense	us-gaap:InterestExpense	\$0	2021-12-31	2022-02-24	10-K	0001108205-22-000002
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$9.4M	2025-12-31	2026-03-24	10-K	0001108205-26-000043
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$10.9M	2024-12-31	2026-03-24	10-K	0001108205-26-000043
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$10.0M	2023-12-31	2025-03-31	10-K	0001108205-25-000031
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$10.2M	2022-12-31	2024-02-08	10-K	0001108205-24-000010
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$38.4M	2023-12-31	2025-03-31	10-K	0001108205-25-000031
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2023-12-31	2024-02-08	10-K	0001108205-24-000010
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$54.3M	2022-12-31	2024-02-08	10-K	0001108205-24-000010
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$416,000	2022-12-31	2024-02-08	10-K	0001108205-24-000010
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$37.6M	2021-12-31	2023-03-13	10-K	0001108205-23-000023
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2021-12-31	2023-03-13	10-K	0001108205-23-000023
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$25.7M	2020-12-31	2022-02-24	10-K	0001108205-22-000002
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$677,000	2020-12-31	2022-02-24	10-K	0001108205-22-000002
25	assets	us-gaap:Assets	\$77.3M	2023-12-31	2025-03-31	10-K	0001108205-25-000031
26	assets	us-gaap:Assets	\$108.8M	2022-12-31	2024-02-08	10-K	0001108205-24-000010
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	39,978,693	2026-03-20	2026-03-24	10-K	0001108205-26-000043
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,487,818	2025-03-27	2025-03-31	10-K	0001108205-25-000031